Which Peptides Are Legal to Prescribe or Compound in 2026?

You can still get FDA-approved peptides prescribed as finished drugs in 2026. BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax sit in a different group. An advisory committee recommended them for possible future compounding in July 2026, but that vote did not make them legal to compound.

What can be prescribed today?

Finished drugs that completed FDA approval remain prescribable. That group includes semaglutide, tirzepatide and liraglutide, plus tesamorelin (Egrifta for HIV-related fat buildup), bremelanotide (Vyleesi for low sexual desire in premenopausal women) and insulin FDA-approved list. You receive these as the approved brand product with a prescription, and tesamorelin has the clearest status for that reason peptide regulation explainer.

BPC-157, TB-500, sermorelin, CJC-1295 and ipamorelin are not FDA-approved as finished drugs FDA-approved list. Sermorelin once had an approved product, which gives it a different compounding history, and clinics have used it off-label for growth hormone support peptide regulation explainer.

Why aren't BPC-157, TB-500, and KPV compoundable yet?

These peptides sit in Category 2. That is FDA's interim label for bulk ingredients where reviewers saw a possible safety concern. Ingredients in Category 2 sit outside the Category 1 approach that lets some ingredients be compounded while FDA finishes review, so pharmacies cannot compound them under 503A while they wait for a final decision compounding update. 503A is the law that lets a licensed pharmacy prepare a prescription for one person when no suitable finished drug exists.

On July 23-24, 2026, the advisory group on compounding (PCAC) reviewed seven bulk ingredients, and FDA proceeded on BPC-157 even after the original nominators withdrew their requests FDA briefing document. The group recommended six families for possible addition to the 503A list, BPC-157, KPV, TB-500 described as thymosin beta-4 fragment LKKTETQ, MOTS-c, Epitalon and Semax, and did not recommend emideltide also called DSIP compounding update. That recommendation did not authorize compounding that day.

What about GHK-Cu and other glow peptides?

GHK-Cu, the peptide many women ask about for skin appearance, sits on a separate track. FDA returned the non-injectable forms to Category 1, which means under evaluation, after a nominator clarified that it had withdrawn only the injectable form FDA bulks list.

FDA said it plans to bring GHK-Cu to the advisory committee before the end of February 2027, along with LL-37, dihexa acetate, Melanotan II and PEG-MGF compounding update. Until FDA adds a Category 2 ingredient to the 503A list with a final decision, a 503A pharmacy cannot compound it under 503A.